Next-generation dendritic cell-based vaccines

Learn how enrichment of primary dendritic cell (DC) subsets and sustainable DC manufacturing advances DC-based cell therapies. In the last decade, several DC-based vaccination and other pioneering immunotherapeutic treatments have paved the way to a new personalized approach to cancer treatment. DC–based vaccination aims to enhance the immune system’s ability to attack the tumor. However, limitations like low efficacy and low sustainability of the manufacturing process are still a challenge for DC-based therapies. This webinar gives insights on how to tackle these challenges in next-generation DC manufacturing: We will focus on enrichment of primary DC subsets from peripheral blood (blood DCs), possible combination with other immunotherapeutic approaches, and increasing manufacturing sustainability with the CliniMACS Prodigy® Platform.

 

Learning Objectives